NCT00472147

Brief Summary

Sudden cardiac death is the most frequent cause of death in industrialized countries. The most efficient interventiont in ventricular fibrillation is defibrillation in an appropriate timely manner. But since the intervention of defibrillation the optimal shock energy is unknown. As a too low energy is not able to terminate ventricular fibrillation a too high energy may cause asystole wich jeopardizes survival itself. We study the efficacy of different shock energies on the termination of ventricular fibrillatiion and survival.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 10, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 11, 2007

Completed
Last Updated

May 11, 2007

Status Verified

May 1, 2007

First QC Date

May 10, 2007

Last Update Submit

May 10, 2007

Conditions

Sudden Cardiac DeathArrhythmiaSurvival

Outcome Measures

Primary Outcomes (1)

  • termination of vf survival

Secondary Outcomes (1)

  • resulting rhythm CPC score

Interventions

shock efficacyPROCEDURE

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • out of hospital sudden cardiac death
  • ventricular fibrillation

You may not qualify if:

  • non cardiac death
  • asystole

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Charité campus Benjamin Franklin

Berlin, State of Berlin, 12200, Germany

Location

MeSH Terms

Conditions

Death, Sudden, CardiacArrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart ArrestHeart DiseasesCardiovascular DiseasesDeath, SuddenDeathPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Dirk Müller, MD, PhD

    Charite University, Berlin, Germany

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dirk Müller, MD, PhD

CONTACT

+49 30 8445dr.dirk.mueller@charite.de

Hans-Richard Arntz, MD, PhD

CONTACT

+49 30 8445hans-richard.arntz@charite.de

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 10, 2007

First Posted

May 11, 2007

Last Updated

May 11, 2007

Record last verified: 2007-05

Locations

DE(1)